|Systematic (IUPAC) name|
|Mol. mass||286.391 g/mol|
BW-723C86 is a tryptamine derivative drug which acts as a 5-HT2B receptor agonist. It has anxiolytic effects in animal studies, and is also used for investigating the function of the 5-HT2B receptor in a range of other tissues.
BW-723C86 is actually a mixed 5-HT2B / 5-HT2C agonist, and while it has good selectivity over 5-HT2A and other serotonin receptor subtypes, it has only around 3x selectivity for 2B over 2C and so is much less selective than most research ligands, but no superior 5-HT2B agonist was available until the potent and selective 5-HT2B activity of 6-APB was discovered in 2012. Highly selective 5-HT2C antagonists are available however, and so a combination of BW-723C86 with a selective 5-HT2C antagonist allows 5-HT2B mediated responses to be studied in isolation.
- Kennett, GA, Bright, F, Trail, B, Baxter, GS, Blackburn, TP (April 1996). "Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety".
- Kennett, GA, Trail, B, Bright, F (December 1998). "Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated". Neuropharmacology 37 (12): 1603–10.
- Knowles, ID, Ramage, AG (January 2000). "Evidence that activation of central 5-HT2B receptors causes renal sympathoexcitation in anaesthetized rats". British Journal of Pharmacology 129 (1): 177–83.
- Günther, S, Maroteaux, L, Schwarzacher, SW (August 2006). "Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro". Journal of Neurobiology 66 (9): 949–61.
- Ryan, BK, Anwyl, R, Rowan, MJ (August 2008). "5-HT2 receptor-mediated reversal of the inhibition of hippocampal long-term potentiation by acute inescapable stress". Neuropharmacology 55 (2): 175–82.
- Iversen, L.; Gibbons, S.; Treble, R.; Setola, V.; Huang, X. P.; Roth, B. L. (2012). "Neurochemical profiles of some novel psychoactive substances". European Journal of Pharmacology.